News
AXSM
188.69
-0.16%
-0.30
Weekly Report: what happened at AXSM last week (0413-0417)?
Weekly Report · 1d ago
Axsome Is Priced For Perfection Ahead Of Auvelity's Alzheimer's Agitation Decision
Seeking Alpha · 04/13 18:17
Weekly Report: what happened at AXSM last week (0406-0410)?
Weekly Report · 04/13 10:38
Axsome Therapeutics Is Maintained at Buy by UBS
Dow Jones · 04/10 16:21
UBS Maintains Buy on Axsome Therapeutics, Raises Price Target to $259
Benzinga · 04/10 16:11
AXSOME THERAPEUTICS INC <AXSM.O>: UBS RAISES TARGET PRICE TO $259 FROM $251
Reuters · 04/10 13:22
Axsome Therapeutics price target raised to $259 from $251 at UBS
TipRanks · 04/10 10:20
U.S. RESEARCH ROUNDUP-Chevron, Littelfuse, Parker-Hannifin
Reuters · 04/10 07:38
Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
TipRanks · 04/09 13:15
Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating
TipRanks · 04/09 10:16
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
TipRanks · 04/09 01:48
Axsome Therapeutics to report first-quarter results, host conference call
Reuters · 04/08 11:00
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
Barchart · 04/08 06:00
Weekly Report: what happened at AXSM last week (0330-0403)?
Weekly Report · 04/06 10:39
Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
TipRanks · 04/02 14:15
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/02 11:30
Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)
TipRanks · 04/02 10:20
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Benzinga · 04/01 17:36
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Reuters · 04/01 16:14
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Reuters · 04/01 13:14
More
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include Auvelity, Sunosi and Symbravo. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, AXS-14 and AXS-17. Its lead product candidate, AXS-05 (dextromethorphan and bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. It also owns balipodect, a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor for the treatment of schizophrenia and Tourette syndrome.